These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9062488)

  • 1. Aspirin inhibits vasopressin-induced hypothalamic-pituitary-adrenal activity in normal humans.
    Nye EJ; Hockings GI; Grice JE; Torpy DJ; Walters MM; Crosbie GV; Wagenaar M; Cooper M; Jackson RV
    J Clin Endocrinol Metab; 1997 Mar; 82(3):812-7. PubMed ID: 9062488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin increases the human hypothalamic-pituitary-adrenal axis response to naloxone stimulation.
    Hockings GI; Grice JE; Crosbie GV; Walters MM; Jackson AJ; Jackson RV
    J Clin Endocrinol Metab; 1993 Aug; 77(2):404-8. PubMed ID: 8393884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans.
    Torpy DJ; Grice JE; Hockings GI; Walters MM; Crosbie GV; Jackson RV
    J Clin Endocrinol Metab; 1994 Jul; 79(1):140-4. PubMed ID: 8027217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity.
    Vicennati V; Ceroni L; Gagliardi L; Pagotto U; Gambineri A; Genghini S; Pasquali R
    J Endocrinol Invest; 2004 Jun; 27(6):541-7. PubMed ID: 15717651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans.
    Arvat E; Maccagno B; Giordano R; Pellegrino M; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3176-81. PubMed ID: 11443185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects.
    Rubin RT; O'Toole SM; Rhodes ME; Sekula LK; Czambel RK
    Psychiatry Res; 1999 Dec; 89(1):1-20. PubMed ID: 10643873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia.
    Ryan MC; Sharifi N; Condren R; Thakore JH
    Psychoneuroendocrinology; 2004 Sep; 29(8):1065-70. PubMed ID: 15219658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion.
    Mastorakos G; Weber JS; Magiakou MA; Gunn H; Chrousos GP
    J Clin Endocrinol Metab; 1994 Oct; 79(4):934-9. PubMed ID: 7962300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans.
    Grottoli S; Maccagno B; Ramunni J; Di Vito L; Giordano R; Gianotti L; DeStefanis S; Camanni F; Ghigo E; Arvat E
    J Endocrinol Invest; 2002 May; 25(5):420-5. PubMed ID: 12035937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate agonists activate the hypothalamic-pituitary-adrenal axis through hypothalamic paraventricular nucleus but not through vasopressinerg neurons.
    Zelena D; Mergl Z; Makara GB
    Brain Res; 2005 Jan; 1031(2):185-93. PubMed ID: 15649443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-adrenal axis.
    Lizcano F; Salvador J
    Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1085-90. PubMed ID: 18505442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of urocortin I on the hypothalamic ACTH secretagogues and its impact on the hypothalamic-pituitary-adrenal axis.
    Bagosi Z; Csabafi K; Palotai M; Jászberényi M; Földesi I; Gardi J; Szabó G; Telegdy G
    Neuropeptides; 2014 Feb; 48(1):15-20. PubMed ID: 24331779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of nitric oxide synthase inhibitors on the vasopressin-induced pituitary-adrenocortical activity and hypothalamic catecholamine levels.
    Bugajski J; Gadek-Michalska A; Głód R; Borycz J
    J Physiol Pharmacol; 1998 Dec; 49(4):617-26. PubMed ID: 10069702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Maccario M; Giordano R; Broglio F; Camanni F; Ghigo E
    Eur J Endocrinol; 2000 Jul; 143(1):99-104. PubMed ID: 10870037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of adrenocorticotropin (ACTH) stimulation tests and insulin hypoglycemia in normal humans: low dose, standard high dose, and 8-hour ACTH-(1-24) infusion tests.
    Nye EJ; Grice JE; Hockings GI; Strakosch CR; Crosbie GV; Walters MM; Jackson RV
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3648-55. PubMed ID: 10523009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cyclooxygenase inhibitors on the vasopressin induced ACTH and corticosterone response during crowding stress.
    Bugajski J; Gadek-Michalska A
    J Physiol Pharmacol; 2003 Jun; 54(2):247-56. PubMed ID: 12832725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cocaine- and amphetamine-regulated transcript activates the hypothalamic-pituitary-adrenal axis through a corticotropin-releasing factor receptor-dependent mechanism.
    Smith SM; Vaughan JM; Donaldson CJ; Rivier J; Li C; Chen A; Vale WW
    Endocrinology; 2004 Nov; 145(11):5202-9. PubMed ID: 15271883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The acute effects of oral ethanol on the hypothalamic-pituitary-adrenal axis in normal human subjects.
    Inder WJ; Joyce PR; Wells JE; Evans MJ; Ellis MJ; Mattioli L; Donald RA
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):65-71. PubMed ID: 7889634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticotropin-releasing hormone and the sympathoadrenal system are major mediators in the effects of peripherally administered exendin-4 on the hypothalamic-pituitary-adrenal axis of male rats.
    Gil-Lozano M; Romaní-Pérez M; Outeiriño-Iglesias V; Vigo E; González-Matías LC; Brubaker PL; Mallo F
    Endocrinology; 2014 Jul; 155(7):2511-23. PubMed ID: 24731096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct evidence that stimulation of neuropeptide Y Y5 receptor activates hypothalamo-pituitary-adrenal axis in conscious rats via both corticotropin-releasing factor- and arginine vasopressin-dependent pathway.
    Kakui N; Kitamura K
    Endocrinology; 2007 Jun; 148(6):2854-62. PubMed ID: 17363455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.